Literature DB >> 19648942

Therapy: Guidelines in rheumatology: quo vadis?

Arthur Kavanaugh1.   

Abstract

The choice of optimum second-line DMARDs for patients with rheumatoid arthritis is fraught with challenges. The implementation of evidence-based guidelines designed to inform clinicians' decisions requires careful consideration of several important issues.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19648942     DOI： 10.1038/nrrheum.2009.146

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  4 in total

1.  What is a NICE-SUGAR for patients in the intensive care unit?

Authors:  Rinaldo Bellomo; Moritoki Egi
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

2.  Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Authors:  P Emery; R Van Vollenhoven; M Ostergaard; E Choy; B Combe; W Graninger; K Krueger; M Matucci-Cerinic; F Navarro; P van Riel; L Settas; S Steinfeld
Journal:  Ann Rheum Dis       Date:  2009-04       Impact factor: 19.103

Review 3.  Quality of care in rheumatic diseases: performance measures and improvement.

Authors:  J Timothy Harrington
Journal:  Curr Opin Rheumatol       Date:  2008-03       Impact factor: 5.006

4.  Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.

Authors:  Bruno Fautrel; Francis Guillemin; Olivier Meyer; Michel de Bandt; Jean-Marie Berthelot; René-Marc Flipo; Frédéric Lioté; Jean-Francis Maillefert; Daniel Wendling; Alain Saraux; Bernard Combe; Xavier Le Loët
Journal:  Arthritis Rheum       Date:  2009-04-15
  4 in total
  1 in total

1.  Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia.

Authors:  Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2010-09       Impact factor: 20.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.